Vortioxetine (hydrobromide) (Standard)

[1]Bang-Andersen B, et al. Discovery of 1-[2- (2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004) : a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54 (9) :3206-21.|[2]Guilloux JP, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 May 28;73C:147-159.|[3]Theunissen EL, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93 (6) :493-501.|[4]Rothschild AJ, et al. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22 (12) :858-66.|[5]Mork A, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340 (3) :666-75.